These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31877828)

  • 1. Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure.
    Tay E; Nguyen TH; Ford L; Williams HD; Benameur H; Scammells PJ; Porter CJH
    Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31877828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.
    Sahbaz Y; Williams HD; Nguyen TH; Saunders J; Ford L; Charman SA; Scammells PJ; Porter CJ
    Mol Pharm; 2015 Jun; 12(6):1980-91. PubMed ID: 25905624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies.
    Sahbaz Y; Nguyen TH; Ford L; McEvoy CL; Williams HD; Scammells PJ; Porter CJH
    Mol Pharm; 2017 Nov; 14(11):3669-3683. PubMed ID: 28954512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
    Tanaka Y; Doi H; Katano T; Kasaoka S
    Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
    Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
    J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA; Chalmers DK; Pouton CW; Porter CJH
    Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ
    Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
    Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation.
    Sirvi A; Jadhav K; Sangamwar AT
    Int J Pharm; 2024 May; 656():124108. PubMed ID: 38604540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.
    Tanaka Y; Nguyen TH; Suys EJA; Porter CJH
    Mol Pharm; 2021 Apr; 18(4):1768-1778. PubMed ID: 33729806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.
    Williams HD; Ford L; Han S; Tangso KJ; Lim S; Shackleford DM; Vodak DT; Benameur H; Pouton CW; Scammells PJ; Porter CJH
    Mol Pharm; 2018 Dec; 15(12):5678-5696. PubMed ID: 30376336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
    Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationalizing Counterion Selection for the Development of Lipophilic Salts: A Case Study with Venetoclax.
    Ryan CD; Griffin BT; O'Shea JP
    Mol Pharm; 2024 Jun; 21(6):2981-2992. PubMed ID: 38703358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax.
    Koehl NJ; Henze LJ; Holm R; Kuentz M; Keating JJ; De Vijlder T; Marx A; Griffin BT
    J Pharm Sci; 2022 Jan; 111(1):164-174. PubMed ID: 34516990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW;
    J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations.
    Lai A; Sahbaz Y; Ford L; Nguyen TH; Haque S; Williams HD; Benameur H; Scammells PJ; Porter CJH
    Int J Pharm; 2021 Mar; 597():120292. PubMed ID: 33581479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.
    Suys EJA; Brundel DHS; Chalmers DK; Pouton CW; Porter CJH
    J Control Release; 2021 Mar; 331():45-61. PubMed ID: 33450318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition.
    Paulus F; Holm R; Stappaerts J; Bauer-Brandl A
    Eur J Pharm Sci; 2024 Jun; 197():106765. PubMed ID: 38608735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 50years of oral lipid-based formulations: Provenance, progress and future perspectives.
    Feeney OM; Crum MF; McEvoy CL; Trevaskis NL; Williams HD; Pouton CW; Charman WN; Bergström CAS; Porter CJH
    Adv Drug Deliv Rev; 2016 Jun; 101():167-194. PubMed ID: 27089810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.